Tumor and liver drug uptake following hepatic artery and portal vein infusion

Journal Article · Sat Oct 31 23:00:00 EST 1987 · J. Clin. Oncol.; (United States)

OSTI ID:5606385

Sigurdson, E R; Ridge, J A; Kemeny, N; Daly, J M

Anatomic dye injection studies of the blood supply of colorectal hepatic metastases suggest that tumors are supplied predominantly by the hepatic artery. Using /sup 13/N amino acids with dynamic gamma camera imaging in patients with colorectal hepatic metastases, it has been shown that hepatic artery infusion results in a significantly greater nutrient delivery to tumor compared with portal vein infusion. However, direct measurements of drug levels in tumor following hepatic artery and portal vein infusion in humans have not previously been reported. Patients with metastatic colorectal cancer confined to the liver received fluorodeoxyuridine (FUdR) through the hepatic artery or through the portal vein. All patients had previously failed systemic chemotherapy. Five patients with hepatic artery catheters were matched (by age, serum lactic dehydrogenase levels, percent hepatic replacement, and tumor size) with five patients with portal vein catheters. At operation, /sub 3/H-FUdR (1 microCi/kg) and /sup 99m/Tc-macroaggregated albumin (MAA) (6 mCi) were injected into the hepatic artery or portal vein. Liver and tumor biopsies were obtained two and five minutes later. /sub 3/H and /sup 99m/Tc were measured per gram tissue by scintillation and gamma counting. The mean liver levels following hepatic artery infusion (23.9 +/- 11.4 nmol/g) and portal vein infusion (18.4 +/- 14.5 nmol/g) did not differ. However, the mean tumor FUdR level following hepatic artery infusion was 12.4 +/- 12.2 nmol/g, compared with a mean tumor FUdR level following portal vein infusion of 0.8 +/- 0.7 nmol/g (P less than .01). This low level of tumor drug uptake after portal vein infusion of FUdR predicts minimal tumor response to treatment via this route. Thus, regional chemotherapy for established colorectal hepatic metastases should be administered through the hepatic artery.

• Research Organization: Memorial Sloan-Kettering Cancer Center, New York, NY
• OSTI ID: 5606385
• Journal Information: J. Clin. Oncol.; (United States), Journal Name: J. Clin. Oncol.; (United States) Vol. 5:11; ISSN JCOND
• Country of Publication: United States
• Language: English

Related Subjects

550600* -- Medicine
550601 -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
ANIMALS
ANTI-INFECTIVE AGENTS
ANTIMETABOLITES
ANTIMICROBIAL AGENTS
ARTERIES
AZINES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BLOOD VESSELS
BODY
CAMERAS
CARDIOVASCULAR SYSTEM
CHEMOTHERAPY
COUNTING TECHNIQUES
DIGESTIVE SYSTEM
DISEASES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
FLUOROURACILS
FUDR
GAMMA CAMERAS
GASTROINTESTINAL TRACT
GLANDS
HETEROCYCLIC COMPOUNDS
HOURS LIVING RADIOISOTOPES
HYDROXY COMPOUNDS
INFUSION
INTAKE
INTERMEDIATE MASS NUCLEI
INTESTINES
ISOMERIC NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LABELLED COMPOUNDS
LARGE INTESTINE
LIGHT NUCLEI
LIVER
MAMMALS
MAN
METASTASES
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NITROGEN 13
NITROGEN ISOTOPES
NUCLEI
NUCLEOSIDES
NUCLEOTIDES
ODD-EVEN NUCLEI
ORGANIC COMPOUNDS
ORGANIC FLUORINE COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PRIMATES
PYRIMIDINES
RADIOISOTOPES
RADIOSENSITIZERS
RECTUM
RIBOSIDES
SCINTILLATION COUNTING
TECHNETIUM 99
TECHNETIUM ISOTOPES
THERAPY
TRACER TECHNIQUES
TRITIUM COMPOUNDS
UPTAKE
URACILS
VEINS
VERTEBRATES
YEARS LIVING RADIOISOTOPES